Chimerix Inc. named Peter Payne senior vice president of business development and corporate strategy, and Roberto Guzman vice president of corporate compliance on Monday.
The biopharmaceutical company, which develops oral antivirals, is currently working on treatments for the human papilloma virus (HPV), cytomegalovirus (CMV), adenovirus (ADV) and Ebola.
Payne most recently served as a strategy consultant with Quantum Leap Healthcare. He also was the co-founder and CEO of eXcelerate Research.
He holds an honors degree in pharmacology from the University of Manchester in the United Kingdom and post-graduate degrees from the University of North Carolina and the University of Chicago Graduate School of Business.
Guzman, who most recently served as corporate regulatory affairs director at Smith and Nephew, received his law degree from the Pontifical Catholic University of Puerto Rico.
He also has a master's degree in chemical and life sciences from the University of Maryland-College Park, as well as an MBA from the University of Massachusetts-Lowell and a bachelor's degree in industrial engineering from Polytechnic University.
"We continue to build our corporate infrastructure and expand our management team in critical areas of the company with the appointments of Peter and Roberto," M. Michelle Berrey, Chimerix president and CEO, said. "Peter and Roberto bring much-needed expertise in the areas of business development, operations and quality that are essential for Chimerix to continue on this trajectory of success."